Stinne Ravn Greisen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Stinne Ravn Greisen has a total of 179 co-authors. Here are the top co-authors by number of shared publications:
- Bent Deleuran
Department of Biomedicine Aarhus University Aarhus Denmark
21 shared publications Malene Hvid
Department of Biomedicine, Aarhus University, Aarhus, Denmark; Department of Clinical Medicine, Aarhus University, Aarhus, Denmark
8 shared publications- Merete Lund Hetland
Department of Clinical Medicine, Faculty of Health and Medical Sciences University of Copenhagen Copenhagen Denmark
6 shared publications - Tue Wenzel Kragstrup
Department of Biomedicine Aarhus University Aarhus Denmark
6 shared publications - Kim Hørslev-Petersen
Department of Regional Health Research, University of Southern Denmark, Region of Southern, Denmark, Denmark
5 shared publications Bent Deleuran
Department of Biomedicine Aarhus University Aarhus Denmark
4 shared publications
Latest Publications
- Open Access
Autoantibodies From Connective Tissue Diseases Penetrate Cells and Exert Functional Properties
Antinuclear antibodies (ANAs) are a hallmark of connective tissue diseases (CTDs) and serve as robust diagnostic biomarkers. Because their cognate antigens are intracellular, ANAs have long been considered non-pathogenic in CTDs. Here, using systemic sclerosis (SSc) associated anti-topoisomerase I antibodies (ATAs) as a model, we provide data challenging this view. We show that ANAs enter living cells, accumulate in nuclei, and engage their intracellular antigen. Nuclear ATAs inhibit topoisomerase I enzymatic activity, induces DNA damage, fibrosis, and, through the STING pathway, activates type I interferon production. We further identify neonatal Fc receptor (FcRn)-dependent intracellular trafficking as a key determinant of ANAs nuclear access and demonstrate that pharmacological FcRn blockade impairs ATAs functionality. These findings reveal a previously unrecognized intracellular effector function of ANAs and establish a mechanistic framework by which ANAs may directly contribute to tissue injury in CTDs.
Open AccessAutoantibodies From Connective Tissue Diseases Penetrate Cells and Exert Functional Properties
Antinuclear antibodies (ANAs) are a hallmark of connective tissue diseases (CTDs) and serve as robust diagnostic biomarkers. Because their cognate antigens are intracellular, ANAs have long been considered non-pathogenic in CTDs. Here, using systemic sclerosis (SSc) associated anti-topoisomerase I antibodies (ATAs) as a model, we provide data challenging this view. We show that ANAs enter living cells, accumulate in nuclei, and engage their intracellular antigen. Nuclear ATAs inhibit topoisomerase I enzymatic activity, induces DNA damage, fibrosis, and, through the STING pathway, activates type I interferon production. We further identify neonatal Fc receptor (FcRn)-dependent intracellular trafficking as a key determinant of ANAs nuclear access and demonstrate that pharmacological FcRn blockade impairs ATAs functionality. These findings reveal a previously unrecognized intracellular effector function of ANAs and establish a mechanistic framework by which ANAs may directly contribute to tissue injury in CTDs.
- Open Access
- 16 May 2026
- Published by Elsevier in EULAR Rheumatology Open
- Vol. 2 (3)
4-Octyl itaconate inhibits synovial fibroblast activation by targeting Nrf2 to exert anti-inflammatory effects in rheumatoid arthritis
- 16 May 2026
- Published by Elsevier in EULAR Rheumatology Open
- Vol. 2 (3)
Open Access4-Octyl itaconate inhibits synovial fibroblast activation by targeting Nrf2 to exert anti-inflammatory effects in rheumatoid arthritis
- Open Access
- 10 February 2026
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 85 (9) , 1811-1824
Engaging the PD-1 pathway in systemic sclerosis attenuates inflammation-driven fibrosis
- 10 February 2026
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 85 (9) , 1811-1824
Open AccessEngaging the PD-1 pathway in systemic sclerosis attenuates inflammation-driven fibrosis
- Open Access
- 11 January 2026
- Published by Wiley in ACR Open Rheumatology
- Vol. 8 (1) , e70120
Lymphocyte Activation Gene 3 Regulation of Profibrotic Cytokines and Type I Collagen Production in Patients With Systemic Sclerosis
Objective: Diffuse cutaneous systemic sclerosis (dcSSc) is characterized by skin and internal organ fibrosis. The regulatory aspects of the immune system involved in maintaining tolerance are still poorly understood in dcSSc. The late checkpoint inhibitory lymphocyte activation gene 3 (LAG‐3) is implicated in T cell inhibition by interacting with its ligand, major histocompatibility complex class II. Its role in dcSSc has yet to be established. Methods: Plasma soluble LAG‐3 (sLAG‐3) levels of 35 patients with dcSSc were compared with the levels of 20 healthy controls (HCs). Peripheral blood mononuclear cell (PBMC) samples from patients with dcSSc (n = 8) and HCs (n = 8) were analyzed by flow cytometry for the surface expression of LAG‐3 on CD4+ and CD8+ T cells after CD3/CD28 stimulation. The dcSSc PBMCs were stimulated (anti‐CD3/CD28), kept as monocultures, or cocultured with autologous dermal fibroblasts and treated with a LAG‐3 agonistic antibody or isotype control. The supernatants were analyzed for proinflammatory cytokines, extracellular matrix proteins, and bioactive type I interferon (IFN). Results: Patients with dcSSc had a two‐fold decreased sLAG‐3 level compared with HCs ( P < 0.0001). Increased surface expression of LAG‐3 was observed in activated CD4+ T cells and CD8+ T cells in patients with dcSSc compared to HC PBMCs. The LAG‐3 agonistic antibody decreased IFNγ, interleukin‐4, and tumor necrosis factor α levels in supernatants from PBMCs and dermal fibroblast cocultures. Furthermore, we observed decreased pro collagen, fibronectin, and IFNα/β bioactivity in the cocultures. Conclusion: LAG‐3 is immunoregulatory in dcSSc, and a LAG‐3 agonistic antibody is a potential treatment modality.
- 11 January 2026
- Published by Wiley in ACR Open Rheumatology
- Vol. 8 (1) , e70120
Open AccessLymphocyte Activation Gene 3 Regulation of Profibrotic Cytokines and Type I Collagen Production in Patients With Systemic Sclerosis
Objective: Diffuse cutaneous systemic sclerosis (dcSSc) is characterized by skin and internal organ fibrosis. The regulatory aspects of the immune system involved in maintaining tolerance are still poorly understood in dcSSc. The late checkpoint inhibitory lymphocyte activation gene 3 (LAG‐3) is implicated in T cell inhibition by interacting with its ligand, major histocompatibility complex class II. Its role in dcSSc has yet to be established. Methods: Plasma soluble LAG‐3 (sLAG‐3) levels of 35 patients with dcSSc were compared with the levels of 20 healthy controls (HCs). Peripheral blood mononuclear cell (PBMC) samples from patients with dcSSc (n = 8) and HCs (n = 8) were analyzed by flow cytometry for the surface expression of LAG‐3 on CD4+ and CD8+ T cells after CD3/CD28 stimulation. The dcSSc PBMCs were stimulated (anti‐CD3/CD28), kept as monocultures, or cocultured with autologous dermal fibroblasts and treated with a LAG‐3 agonistic antibody or isotype control. The supernatants were analyzed for proinflammatory cytokines, extracellular matrix proteins, and bioactive type I interferon (IFN). Results: Patients with dcSSc had a two‐fold decreased sLAG‐3 level compared with HCs ( P < 0.0001). Increased surface expression of LAG‐3 was observed in activated CD4+ T cells and CD8+ T cells in patients with dcSSc compared to HC PBMCs. The LAG‐3 agonistic antibody decreased IFNγ, interleukin‐4, and tumor necrosis factor α levels in supernatants from PBMCs and dermal fibroblast cocultures. Furthermore, we observed decreased pro collagen, fibronectin, and IFNα/β bioactivity in the cocultures. Conclusion: LAG‐3 is immunoregulatory in dcSSc, and a LAG‐3 agonistic antibody is a potential treatment modality.
- Open Access
- 2 October 2024
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 12 (10) , e009952
Gal-3 blocks the binding between PD-1 and pembrolizumab
Introduction Immune checkpoint inhibitors (ICI) have revolutionized the treatment of metastatic malignant melanoma (MM) and improved long-term survival. Despite the impressive results, some patients still have progressive disease, and the search for biomarkers predicting response to ICI treatment is ongoing. In this search, galectin-3 (Gal-3) has been suggested as a molecule of interest, both as a marker of treatment response and as a treatment target to potentiate ICI therapy. We have previously demonstrated the binding between programmed cell death 1 (PD-1) and Gal-3, and here, we investigated the interaction between PD-1, pembrolizumab, and Gal-3 in metastatic MM patients. Methods The binding between PD-1, pembrolizumab and Gal-3 was investigated by surface plasmon resonance (SPR) and cryogenic electron microscopy (cryo-EM). The function was studied in in vitro cultures and soluble levels of both PD-1 and Gal-3 were measured in metastatic MM patients, treated with pembrolizumab. Results By SPR, we demonstrated that Gal-3 can block the binding between PD-1 and pembrolizumab, and further visualized a steric inhibition using cryo-EM. T cells cultured with Gal-3 had reduced pro-inflammatory cytokine production, which could not be rescued by pembrolizumab. In patients with metastatic MM, high levels of Gal-3 in plasma were found in patients with a longer progression-free survival in the study period, whereas high Gal-3 expression in the tumor was seen in patients with disease progression. Soluble PD-1 levels in plasma increased after treatment with pembrolizumab and correlated with disease progression. Conclusion We demonstrate that the interaction between PD-1 and Gal-3 interferes with the binding of pembrolizumab, supporting that an immune suppression induced by Gal-3 in the tumor microenvironment cannot be rescued by pembrolizumab.
- 2 October 2024
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 12 (10) , e009952
Open AccessGal-3 blocks the binding between PD-1 and pembrolizumab
Introduction Immune checkpoint inhibitors (ICI) have revolutionized the treatment of metastatic malignant melanoma (MM) and improved long-term survival. Despite the impressive results, some patients still have progressive disease, and the search for biomarkers predicting response to ICI treatment is ongoing. In this search, galectin-3 (Gal-3) has been suggested as a molecule of interest, both as a marker of treatment response and as a treatment target to potentiate ICI therapy. We have previously demonstrated the binding between programmed cell death 1 (PD-1) and Gal-3, and here, we investigated the interaction between PD-1, pembrolizumab, and Gal-3 in metastatic MM patients. Methods The binding between PD-1, pembrolizumab and Gal-3 was investigated by surface plasmon resonance (SPR) and cryogenic electron microscopy (cryo-EM). The function was studied in in vitro cultures and soluble levels of both PD-1 and Gal-3 were measured in metastatic MM patients, treated with pembrolizumab. Results By SPR, we demonstrated that Gal-3 can block the binding between PD-1 and pembrolizumab, and further visualized a steric inhibition using cryo-EM. T cells cultured with Gal-3 had reduced pro-inflammatory cytokine production, which could not be rescued by pembrolizumab. In patients with metastatic MM, high levels of Gal-3 in plasma were found in patients with a longer progression-free survival in the study period, whereas high Gal-3 expression in the tumor was seen in patients with disease progression. Soluble PD-1 levels in plasma increased after treatment with pembrolizumab and correlated with disease progression. Conclusion We demonstrate that the interaction between PD-1 and Gal-3 interferes with the binding of pembrolizumab, supporting that an immune suppression induced by Gal-3 in the tumor microenvironment cannot be rescued by pembrolizumab.
- 28 July 2023
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 8 (85) , eadd1591
Clonally expanded CD38 hi cytotoxic CD8 T cells define the T cell infiltrate in checkpoint inhibitor–associated arthritis
Immune checkpoint inhibitor (ICI) therapies used to treat cancer, such as anti–PD-1 antibodies, can induce autoimmune conditions in some individuals. The T cell mechanisms mediating such iatrogenic autoimmunity and their overlap with spontaneous autoimmune diseases remain unclear. Here, we compared T cells from the joints of 20 patients with an inflammatory arthritis induced by ICI therapy (ICI-arthritis) with two archetypal autoimmune arthritides, rheumatoid arthritis (RA) and psoriatic arthritis (PsA). Single-cell transcriptomic and antigen receptor repertoire analyses highlighted clonal expansion of an activated effector CD8 T cell population in the joints and blood of patients with ICI-arthritis. These cells were identified as CD38 hi CD127 − CD8 T cells and were uniquely enriched in ICI-arthritis joints compared with RA and PsA and also displayed an elevated interferon signature. In vitro, type I interferon induced CD8 T cells to acquire the ICI-associated CD38 hi phenotype and enhanced cytotoxic function. In a cohort of patients with advanced melanoma, ICI therapy markedly expanded circulating CD38 hi CD127 − T cells, which were frequently bound by the therapeutic anti–PD-1 drug. In patients with ICI-arthritis, drug-bound CD8 T cells in circulation showed marked clonal overlap with drug-bound CD8 T cells from synovial fluid. These results suggest that ICI therapy directly targets CD8 T cells in patients who develop ICI-arthritis and induces an autoimmune pathology that is distinct from prototypical spontaneous autoimmune arthritides.
- 28 July 2023
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 8 (85) , eadd1591
Clonally expanded CD38 hi cytotoxic CD8 T cells define the T cell infiltrate in checkpoint inhibitor–associated arthritis
Immune checkpoint inhibitor (ICI) therapies used to treat cancer, such as anti–PD-1 antibodies, can induce autoimmune conditions in some individuals. The T cell mechanisms mediating such iatrogenic autoimmunity and their overlap with spontaneous autoimmune diseases remain unclear. Here, we compared T cells from the joints of 20 patients with an inflammatory arthritis induced by ICI therapy (ICI-arthritis) with two archetypal autoimmune arthritides, rheumatoid arthritis (RA) and psoriatic arthritis (PsA). Single-cell transcriptomic and antigen receptor repertoire analyses highlighted clonal expansion of an activated effector CD8 T cell population in the joints and blood of patients with ICI-arthritis. These cells were identified as CD38 hi CD127 − CD8 T cells and were uniquely enriched in ICI-arthritis joints compared with RA and PsA and also displayed an elevated interferon signature. In vitro, type I interferon induced CD8 T cells to acquire the ICI-associated CD38 hi phenotype and enhanced cytotoxic function. In a cohort of patients with advanced melanoma, ICI therapy markedly expanded circulating CD38 hi CD127 − T cells, which were frequently bound by the therapeutic anti–PD-1 drug. In patients with ICI-arthritis, drug-bound CD8 T cells in circulation showed marked clonal overlap with drug-bound CD8 T cells from synovial fluid. These results suggest that ICI therapy directly targets CD8 T cells in patients who develop ICI-arthritis and induces an autoimmune pathology that is distinct from prototypical spontaneous autoimmune arthritides.
- 28 June 2023
- Published by Taylor & Francis in Scandinavian Journal of Clinical and Laboratory Investigation
- Vol. 83 (5) , 309-317
Validation of an indirect ELISA assay for assessment of autoantibodies against full-length TRIM21 and its individual domains
Anti-SSA-autoantibodies are common in patients with rheumatologic disease, especially Sjogren's syndrome, systemic lupus erythematosus and rheumatoid arthritis. They consist of both autoantibodies towards Ro60 and Ro52, the latter also known as TRIM21. TRIM21 is an intracellular protein consisting of four domains; PRY/SPRY, Coiled-Coil, B-box and RING. The aim of this study was to establish an indirect ELISA detecting autoantibodies towards both the full-length TRIM21 protein and its four domains. We expressed the five constructs, created, and validated indirect ELISA protocols for each target using plasma from anti-SSA positive patients and healthy controls. Our findings were validated to the clinically used standards. We measured significantly higher levels of autoantibodies towards our full-length TRIM21, and the PRY/SPRY, Coiled-Coil and RING domains in patients compared to healthy controls. No significant difference in the level of autoantibodies were detected against the B-box domain. Our setups had a signal to noise ratio in the range of 30 to 184, and an OD between 2 and 3. Readings did not decline using NaCl of 500 mM as wash, affirming the high binding affinity of the autoantibodies measured. Our protocols allow us to further study the different autoantibodies of anti-SSA positive patients. This creates the possibility to stratify our patients into subgroups regarding autoantibody profile and specific pheno- or endotype.
- 28 June 2023
- Published by Taylor & Francis in Scandinavian Journal of Clinical and Laboratory Investigation
- Vol. 83 (5) , 309-317
Validation of an indirect ELISA assay for assessment of autoantibodies against full-length TRIM21 and its individual domains
Anti-SSA-autoantibodies are common in patients with rheumatologic disease, especially Sjogren's syndrome, systemic lupus erythematosus and rheumatoid arthritis. They consist of both autoantibodies towards Ro60 and Ro52, the latter also known as TRIM21. TRIM21 is an intracellular protein consisting of four domains; PRY/SPRY, Coiled-Coil, B-box and RING. The aim of this study was to establish an indirect ELISA detecting autoantibodies towards both the full-length TRIM21 protein and its four domains. We expressed the five constructs, created, and validated indirect ELISA protocols for each target using plasma from anti-SSA positive patients and healthy controls. Our findings were validated to the clinically used standards. We measured significantly higher levels of autoantibodies towards our full-length TRIM21, and the PRY/SPRY, Coiled-Coil and RING domains in patients compared to healthy controls. No significant difference in the level of autoantibodies were detected against the B-box domain. Our setups had a signal to noise ratio in the range of 30 to 184, and an OD between 2 and 3. Readings did not decline using NaCl of 500 mM as wash, affirming the high binding affinity of the autoantibodies measured. Our protocols allow us to further study the different autoantibodies of anti-SSA positive patients. This creates the possibility to stratify our patients into subgroups regarding autoantibody profile and specific pheno- or endotype.
- Open Access
- 30 December 2022
- Published by Wiley in Scandinavian Journal of Immunology
- Vol. 97 (2)
Galectin‐3 interacts with PD‐1 and counteracts the PD‐1 pathway‐driven regulation of T cell and osteoclast activity in Rheumatoid Arthritis
Rheumatoid arthritis (RA) is an autoimmune disease characterized by joint inflammation and bone erosions. The glycosylated programmed death‐1 (PD‐1) receptor plays an important role in regulating immune responses and maintaining tolerance. In this study, we focus on two features observed in RA: impaired PD‐1 signalling and Galectin‐3 (Gal‐3) upregulation. We hypothesize that Gal‐3 binds PD‐1 and PD‐1 ligands, potentially contributing to impaired PD‐1 signalling. PD‐1 and Gal‐3 levels in RA synovial fluid (SF) and plasma were evaluated by ELISA. PD‐1 and Gal‐3 interaction was examined by Surface Plasmon Resonance and ELISA. PD‐1, PD‐L1 and Gal‐3 expression on mononuclear cells from SF and peripheral blood as well as fibroblast‐like synoviocytes were examined by flow cytometry. Effects of Gal‐3 and PD‐L1 on osteoclast formation was evaluated by tartrate‐resistant acid phosphatase assay. We show that Gal‐3 binds PD‐1 and PD‐L1. Results demonstrated high expression of PD‐1 and Gal‐3 on mononuclear cells, especially from SF. Gal‐3 inhibited PD‐1 signalling when PD‐L1 was present. Furthermore, a role of Gal‐3 in osteoclast formation was observed in vitro, both directly but also through PD‐1:PD‐L1 inhibition. Effects of Gal‐3 on the PD‐1 signalling axis are proposed to be inhibitory, meaning high Gal‐3 levels in the complex synovial microenvironment are not desirable in RA. Preventing Gal‐3's inhibitory role on PD‐1 signalling could, therefore, be a therapeutic target in RA by affecting inflammatory T cell responses and osteoclasts.
- 30 December 2022
- Published by Wiley in Scandinavian Journal of Immunology
- Vol. 97 (2)
Open AccessGalectin‐3 interacts with PD‐1 and counteracts the PD‐1 pathway‐driven regulation of T cell and osteoclast activity in Rheumatoid Arthritis
Rheumatoid arthritis (RA) is an autoimmune disease characterized by joint inflammation and bone erosions. The glycosylated programmed death‐1 (PD‐1) receptor plays an important role in regulating immune responses and maintaining tolerance. In this study, we focus on two features observed in RA: impaired PD‐1 signalling and Galectin‐3 (Gal‐3) upregulation. We hypothesize that Gal‐3 binds PD‐1 and PD‐1 ligands, potentially contributing to impaired PD‐1 signalling. PD‐1 and Gal‐3 levels in RA synovial fluid (SF) and plasma were evaluated by ELISA. PD‐1 and Gal‐3 interaction was examined by Surface Plasmon Resonance and ELISA. PD‐1, PD‐L1 and Gal‐3 expression on mononuclear cells from SF and peripheral blood as well as fibroblast‐like synoviocytes were examined by flow cytometry. Effects of Gal‐3 and PD‐L1 on osteoclast formation was evaluated by tartrate‐resistant acid phosphatase assay. We show that Gal‐3 binds PD‐1 and PD‐L1. Results demonstrated high expression of PD‐1 and Gal‐3 on mononuclear cells, especially from SF. Gal‐3 inhibited PD‐1 signalling when PD‐L1 was present. Furthermore, a role of Gal‐3 in osteoclast formation was observed in vitro, both directly but also through PD‐1:PD‐L1 inhibition. Effects of Gal‐3 on the PD‐1 signalling axis are proposed to be inhibitory, meaning high Gal‐3 levels in the complex synovial microenvironment are not desirable in RA. Preventing Gal‐3's inhibitory role on PD‐1 signalling could, therefore, be a therapeutic target in RA by affecting inflammatory T cell responses and osteoclasts.
- Open Access
- 16 June 2022
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 13, 883733
Co-Inhibitory Molecules – Their Role in Health and Autoimmunity; Highlighted by Immune Related Adverse Events
Immune checkpoint receptors are key players in regulating the immune response. They are responsible for both generating an immune response sufficient to kill invading pathogens, balancing the same response, and protecting against tissue destruction or the development of autoimmune events. The central role of the co-inhibitory receptors also referred to as inhibitory immune checkpoints, including PD-1 and CTLA-4 has become especially evident with the cancer treatments targeting these receptors. Blocking these pathways enhances the immune activity, resulting in both an increased chance of cancer clearance, at the same time induction of immune-related adverse events (irAE). Some of these irAE progress into actual autoimmune diseases with autoantibodies and symptoms, undistinguished from the naturally occurring diseases. This review will take advantage of the lessons learned from immune checkpoint blockade and relate this knowledge to our understanding of the same pathways in naturally occurring autoimmune diseases, mainly focusing on rheumatic diseases.
- 16 June 2022
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 13, 883733
Open AccessCo-Inhibitory Molecules – Their Role in Health and Autoimmunity; Highlighted by Immune Related Adverse Events
Immune checkpoint receptors are key players in regulating the immune response. They are responsible for both generating an immune response sufficient to kill invading pathogens, balancing the same response, and protecting against tissue destruction or the development of autoimmune events. The central role of the co-inhibitory receptors also referred to as inhibitory immune checkpoints, including PD-1 and CTLA-4 has become especially evident with the cancer treatments targeting these receptors. Blocking these pathways enhances the immune activity, resulting in both an increased chance of cancer clearance, at the same time induction of immune-related adverse events (irAE). Some of these irAE progress into actual autoimmune diseases with autoantibodies and symptoms, undistinguished from the naturally occurring diseases. This review will take advantage of the lessons learned from immune checkpoint blockade and relate this knowledge to our understanding of the same pathways in naturally occurring autoimmune diseases, mainly focusing on rheumatic diseases.
- Open Access
- 9 March 2022
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 13, 773946
The Programmed Death-1 Pathway Counter-Regulates Inflammation-Induced Osteoclast Activity in Clinical and Experimental Settings
Objective: The programmed death-1 (PD-1) pathway is essential for maintaining self-tolerance and plays an important role in autoimmunity, including rheumatoid arthritis (RA). Here, we investigated how membrane-bound and soluble (s)PD-1 influence bone homeostasis during chronic inflammation, exemplified in RA.Methods: Bone mineral density and bone microstructure were examined in PD-1 and PD-L1 knockout (KO) mice and compared with wild-type (WT) mice. Receptor activator of nuclear factor kappa-B ligand (RANKL) was measured in serum, and the expression examined on activated bone marrow cells. Osteoclast formation was examined in cells from murine spleen and bone marrow and from human synovial fluid cells. sPD-1 was measured in chronic and early (e)RA patients and correlated to markers of disease activity and radiographic scores.Results: PD-1 and PD-L1 KO mice showed signs of osteoporosis. This was supported by a significantly reduced trabecular bone volume fraction and deteriorated microstructure, as well as increased osteoclast formation and an increased RANKL/OPG ratio. The recombinant form of sPD-1 decreased osteoclast formationin vitro, but was closely associated with disease activity markers in eRA patients. Sustained elevated sPD-1 levels indicated ongoing inflammation and were associated with increased radiographic progression.Conclusion: The PD-1 pathway is closely associated with bone homeostasis, and lacking members of this pathway causes a deteriorated bone structure. The immunological balance in the microenvironment determines how the PD-1 pathway regulates osteoclast formation. In eRA patients, sPD-1 may serve as a biomarker, reflecting residual but clinically silent disease activity and radiographic progression.
- 9 March 2022
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 13, 773946
Open AccessThe Programmed Death-1 Pathway Counter-Regulates Inflammation-Induced Osteoclast Activity in Clinical and Experimental Settings
Objective: The programmed death-1 (PD-1) pathway is essential for maintaining self-tolerance and plays an important role in autoimmunity, including rheumatoid arthritis (RA). Here, we investigated how membrane-bound and soluble (s)PD-1 influence bone homeostasis during chronic inflammation, exemplified in RA.Methods: Bone mineral density and bone microstructure were examined in PD-1 and PD-L1 knockout (KO) mice and compared with wild-type (WT) mice. Receptor activator of nuclear factor kappa-B ligand (RANKL) was measured in serum, and the expression examined on activated bone marrow cells. Osteoclast formation was examined in cells from murine spleen and bone marrow and from human synovial fluid cells. sPD-1 was measured in chronic and early (e)RA patients and correlated to markers of disease activity and radiographic scores.Results: PD-1 and PD-L1 KO mice showed signs of osteoporosis. This was supported by a significantly reduced trabecular bone volume fraction and deteriorated microstructure, as well as increased osteoclast formation and an increased RANKL/OPG ratio. The recombinant form of sPD-1 decreased osteoclast formationin vitro, but was closely associated with disease activity markers in eRA patients. Sustained elevated sPD-1 levels indicated ongoing inflammation and were associated with increased radiographic progression.Conclusion: The PD-1 pathway is closely associated with bone homeostasis, and lacking members of this pathway causes a deteriorated bone structure. The immunological balance in the microenvironment determines how the PD-1 pathway regulates osteoclast formation. In eRA patients, sPD-1 may serve as a biomarker, reflecting residual but clinically silent disease activity and radiographic progression.